Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The study population consisted of treatment-naïve and treatment-experienced adults patients aged 20-65 with HCV RNA level \> 10,000 IU/ml.~Experienced participants included those with a prior relapse or a null response to PegINF/RBV therapy.~-~Exclusion Criteria:Participants with one or more of~* HCV coinfected with hepatitis B virus (HBV)~* human immunodeficiency virus (HIV)~* had any liver disease other than chronic HCV GT4 infection.~* had a history of liver decompensation~* serum a-fetoprotein (AFP) \> 100 ng/ml~* evidence of hepatocellular carcinoma~* major severe illness such as respiratory, renal, heart failure or autoimmune disease~* non-compliance with treatment.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment-naive (Type: ACTIVE_COMPARATOR): Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)
- Treatment-experienced (Type: ACTIVE_COMPARATOR): Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)

Based on this trial design, predict the completion outcome and termination type (if applicable).